NCT07015593Not yet recruiting
Patient Journey in Advanced Gynecologic Cancers
Patient Journey in Conventional Therapy for Primarily Treated Advanced Gynecologic Cancers in China
Source: ClinicalTrials.gov · Last updated 11 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 780 (estimated)
- First submitted
- 4 Jun 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Tongji Hospital
- Diseases
- Endometrial cancer, Cervical cancer
- NCT number
- NCT07015593
What you commit to
- Study type: Observational
- Planned participants: 780
- From 1 Jul 2025 to the primary completion date, 1 Jul 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.
- Previously participated in or participating in a clinical trial.
- Patients who received another line of therapy after initial therapy.
Other
- Unable or unwilling to provide informed consent.
- Not fluent in local language.
- Indicates or exhibits hearing difficulties, which would make a conversation challenging.
Who the study is looking for
- Age 18 or older
- Newly diagnosed stage III or IV CC or EC
- Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis.
- Told by their physician that their disease is stable.
- Patients must have informed consent form (ICF) signed for the study.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dongling Zou Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
| Shuzhong Yao Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Ying Zhou Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| Gang Chen Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.